U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H28N6O2
Molecular Weight 492.5727
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TEPOTINIB

SMILES

CN1CCC(CC1)COc2cnc(-c3cccc(c3)Cn4c(=O)ccc(-c5cccc(c5)C#N)n4)nc2

InChI

InChIKey=AHYMHWXQRWRBKT-UHFFFAOYSA-N
InChI=1S/C29H28N6O2/c1-34-12-10-21(11-13-34)20-37-26-17-31-29(32-18-26)25-7-3-5-23(15-25)19-35-28(36)9-8-27(33-35)24-6-2-4-22(14-24)16-30/h2-9,14-15,17-18,21H,10-13,19-20H2,1H3

HIDE SMILES / InChI

Molecular Formula C29H28N6O2
Molecular Weight 492.5727
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: https://www.ncbi.nlm.nih.gov/pubmed/23553846

Tepotinib is an investigational small molecule inhibitor of the c-Met receptor tyrosine kinase. Alterations of the c-Met signaling pathway are found in various cancer types and correlate with aggressive tumor behavior and poor clinical prognosis. Tepotinib is a potent and selective c-Met inhibitor, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib is currently in Phase I/II trials in liver cancer and lung cancer.

Approval Year

TargetsConditions

Conditions

PubMed

PubMed

TitleDatePubMed
EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
2013 Jun 1
Patents

Sample Use Guides

500 mg of tepotinib tablet once daily orally during each 21 day cycle
Route of Administration: Oral
Tepotinib inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with Tepotinib induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. Tepotinib effectively blocks phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 16:28:56 UTC 2021
Edited
by admin
on Sat Jun 26 16:28:56 UTC 2021
Record UNII
1IJV77EI07
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TEPOTINIB
INN   WHO-DD  
INN   USAN  
Official Name English
MSC-2156119
Code English
TEPOTINIB [WHO-DD]
Common Name English
TEPOTINIB [INN]
Common Name English
MSC2156119
Code English
EMD-1214063
Code English
EMD1214063
Code English
TEPOTINIB [USAN]
Common Name English
MSC-2156119J
Code English
BENZONITRILE, 3-(1,6-DIHYDRO-1-((3-(5-((1-METHYL-4-PIPERIDINYL)METHOXY)-2-PYRIMIDINYL)PHENYL)METHYL)-6-OXO-3-PYRIDAZINYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C1967
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
Code System Code Type Description
PUBCHEM
25171648
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
EPA CompTox
1100598-32-0
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
DRUG BANK
DB15133
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
CAS
1100598-32-0
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
INN
9934
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
ChEMBL
CHEMBL3402762
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
FDA UNII
1IJV77EI07
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
NCI_THESAURUS
C88314
Created by admin on Sat Jun 26 16:28:57 UTC 2021 , Edited by admin on Sat Jun 26 16:28:57 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
CUMULATIVE EXCRETION
URINE
TARGET -> INHIBITOR
IC50
CUMULATIVE EXCRETION
FECAL
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
Protein binding of tepotinib is 98% and is independent of drug concentration at clinically relevant exposures.
TARGET -> INHIBITOR
Tepotinib also inhibited melatonin 2 and imidazoline 1 receptors at clinically achievable concentrations.
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
FECAL
EXCRETED UNCHANGED
URINE
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TRANSPORTER -> SUBSTRATE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION
PHARMACOKINETIC
IN PATIENTS WITH CANCER
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC